ARA Current Clinical Trials | TMC-125 Experimental NNRTI

TMC-125 (Experimental NNRTI)

A study testing the most effective dosing of a new non-nucleoside reverse transcriptase inhibitor.

Background	There is a need for new and effective antiretrovirals. In earlier studies, TMC-125 worked against wild type HIV and drug resistant HIV.
Objective	To determine the most effective dose of TMC-125.
Study Design	This clinical trial is a randomized, Phase II, 48 week study of TMC-125 in volunteers with drug resistant HIV. Volunteers will be randomly assigned to one of three study groups. Two groups will receive different doses of TMC-125 and one group will continue on their regular drug therapy and will be offered TMC-125 at week 12. This study also includes resistance testing via the VirtualPhenotype.
Inclusion Criteria (partial list)	• HIV-positive adult • Viral load greater than 1000 • HIV drug resistance • Currently on HAART for last 3 months OR on a Structured Treatment Interruption
Status __	Enrolling --
For more information about participating in this study in the Los Angeles area, please call 310.358.2429 or e-mail Corie Castro at ccastro@aidsresearch.org
We encourage participation by women and people of color. This ad was reviewed and approved by the AIDS ReSearch Alliance Institutional Review Board in June, 2004.